Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 175 publications
Healthcare resource utilization and costs in patients with multiple myeloma administered ciltacabtagene autoleucel in outpatient versus inpatient settings after one to three prior lines of therapy.
Journal: Journal of comparative effectiveness research
Published: June 29, 2026
When Myeloma Escapes the Bone Marrow: Extramedullary Disease in the Immunotherapy Era.
Journal: Cancers
Published: June 28, 2026
BRIDGE-2M: Optimizing Bridging Therapy Prior to CAR-T Therapy in Multiple Myeloma: A Modified Double-Blind Delphi Panel of US Physicians.
Journal: Advances in therapy
Published: June 01, 2026
Real-world outcomes with BCMA- and GPRC5D-targeting bispecific antibodies in plasma cell leukemia.
Journal: Blood advances
Published: April 21, 2026
Real-World Outcomes with BCMA- and GPRC5D-Targeting Bispecific Antibodies in Plasma Cell Leukemia.
Journal: Blood advances
Published: April 21, 2026
Primary care experiences at the intersection of sexual minority status and long-term mental health conditions in England: a cross-sectional analysis using the English General Practice Patient Survey.
Journal: EClinicalMedicine
Published: April 17, 2026
Neighborhood Socioeconomic Disadvantage and Distance From Treatment Center do not Impact Survival Outcomes of Patients With Non-Hodgkin Lymphoma and Multiple Myeloma Treated With CAR T-Cell Therapies.
Journal: Transplantation and cellular therapy
Published: April 17, 2026
BIO26-048: A Meta-Analytic Evaluation of Efficacy and Safety Between Ide-cel and Cilta-cel in Relapsed/Refractory Multiple Myeloma Based on Clinical Trial and Real-World Data.
Journal: Journal of the National Comprehensive Cancer Network : JNCCN
Published: March 31, 2026
MRD in multiple myeloma: Moving from "minimal" to "measurable".
Journal: Blood reviews
Published: March 24, 2026
Real-world healthcare resource utilization and clinical outcomes among patients with relapsed/refractory multiple myeloma receiving ciltacabtagene autoleucel after four or more prior lines of therapy in inpatient versus outpatient settings.
Journal: Journal of medical economics
Published: March 18, 2026
The Safety and Efficacy of Commercial BCMA-Directed CAR T-Cell Therapy in Systemic AL Amyloidosis With Concurrent Myeloma.
Journal: American journal of hematology
Published: February 20, 2026
Last Updated: 09/26/2026